There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment.
T he current standard of care for the nonsurgical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is concurrent platinum-based chemotherapy and radiotherapy. Unfortunately, however, this approach results in an approximately 50% treatment failure rate in unselected patients. 1, 2 Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody previously reported to be beneficial for such patients, improving survival when given with definitive radiotherapy or with cisplatin and fluorouracil in recurrent or metastatic HNSCC. 3, 4 However, a randomized phase 3 clinical trial (NRG Oncology RTOG 0522) failed to show any improvement in survival with the addition of 8 weeks of cetuximab to cisplatin and radiotherapy. 2 To date, beyond EGFR surface expression, 5 no predictive biomarker of cetuximab response has been identified for these patients. Recently, human papillomavirus, reliably measured by p16 expression, has been established as a prognostic biomarker in HNSCC, with p16-positive patients having a favorable outcome compared with p16-negative patients. 1, 6, 7 One reason for the better prognosis in p16-positive disease is thought to be attributable to immune-mediated mechanisms because cisplatin and radiotherapy expose p16-associated antigens, which are immunogenic, 8 enabling host-mediated immune tumor killing. Consistent with a prior report, 2 p16-positive patients in NRG Oncology RTOG 0522 had improved outcome compared with p16-negative patients. However, there was no benefit of cetuximab treatment when p16 status was considered in NRG Oncology RTOG 0522. One hypothesis put forward is lower EGFR tumor cell staining in p16-positive tumors in NRG Oncology RTOG 0522 vs p16-negative tumors (22% vs 30%). 2 Beyond inhibition of EGFR signaling, however, cetuximab has also been found to work through immune-mediated mechanisms by enhancing adaptive immunity via antibody-dependent cell-mediated cytotoxicity 9,10 and by better enabling cytotoxic T-lymphocyte cross-priming by dendritic cells. 11 Recently, cetuximab combined with chemotherapy was further confirmed to trigger immunogenic cell death in mouse models through increased phagocytosis by dendritic cells.
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These immune-based mechanisms of cetuximab efficacy have not yet been studied in the setting of radiotherapy, although radiotherapy also enables antitumor immunity, with the release of danger signals, and dendritic and T-cell activation. [13] [14] [15] Recently, a biomarker of altered immune function, FCGR2A, a polymorphism in an Fcy receptor, was found to influence the response rate to cetuximab for patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) (OMIM 190070)-mutant tumors, 16 indicating that inherited polymorphisms can affect cetuximab response. In colon cancer, response to cetuximab is associated with an inherited biomarker disrupting KRAS, referred to as the KRAS-variant.
17 The KRAS-variant is the first microRNAbinding site mutation discovered in cancer and is a functional germline mutation in the 3′ untranslated region of KRAS. Although the mechanisms leading to the predictive power of the KRAS-variant in treatment response have not been fully elucidated, one could hypothesize that the KRAS-variant identifies patients with altered immunity based on the fact that KRAS signaling and let-7 microRNA expression, both universally abnormal in KRAS-variant-associated tumors, 19, 23, 29 are critical in systemic immunity. 32, 33 In addition, mutant KRAS directly inhibits antitumor immunity through induction of transforming growth factor β1 (TGF-β1) secretion, which is known to lead to conversion of conventional T cells into regulatory T cells or type 17 helper T cells. [34] [35] [36] In the setting of radiotherapy, TGF-β1 is proposed to be a master regulator of treatment response, with high levels preventing radiation-induced antitumor immunity.
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Interestingly, in cells with high TGF-β1 levels, cetuximab has been found to restore the killing activity of patient natural killer cells against primary HNSCC cells via enhanced antibodydependent cell-mediated cytotoxicity in a dose-dependent manner. 38 Cetuximab response has also been found to overcome TGF-β1-expressing regulatory T cells, known to inhibit natural killer cell killing, 39 providing a potential mechanism of action. To date, the role of altered immunity and TGF-β1 levels as potential mechanisms of cetuximab response in patients with the KRAS-variant has not been evaluated. Thus, we sought to test the predictive role of the KRASvariant for outcomes in patients with HNSCC in the setting of radiotherapy, cisplatin, and cetuximab, considering p16 status. We further evaluated immunity in patients with the KRASvariant through plasma TGF-β1 levels.
by all institutional review boards where patients were enrolled, and oral informed consent was obtained from all study participants. Race and sex data were collected and are reported in eTable 1 in the Supplement. Eligible patients had pathologically proven squamous cell carcinoma of the oropharynx, hypopharynx, or larynx, with selected stage III or IV disease (T2N2-3M0 or T3-4NM0 [any N]), Zubrod performance status of 0 to 1, age of 18 years or older, and adequate bone marrow, hepatic, and renal function. Human papillomavirus status was evaluated by p16 expression as previously described. 1 
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Of the 70 patients with the KRAS-variant, the cetuximab-treated subset had fewer patients of white race (28 [87.5%] of 32 vs 38 [100%] of 38, P = .04). Within the nonvariant cohort, the cetuximab-treated subset had a significantly younger age than the subset not receiving cetuximab, but the difference in medians was only 2 years (59 vs 57 years, 174 cetuximab treated vs 169 not cetuximab treated, P = .05) (eTable 2 in the Supplement).
KRAS-Variant Testing
Genomic DNA from peripheral blood mononuclear cells or whole blood was isolated as previously described, 40 and 100 ng was analyzed in a Clinical Laboratory Improvement Amendments-certified laboratory for the KRAS-variant (MiraDx). Patients that were homozygous (GG) were grouped with those that were heterozygous (TG) for these analyses.
Plasma TGF-β1 Levels
Plasma levels of TGF-β1 from 376 patients enrolled in NRG Oncology RTOG 0522 were measured using multiplex bead assays with the use of reagents from Millipore and the Luminex 100 system as previously described. 41 The assay was run using manufacturer controls to ensure precision. The correlation between KRAS-variant status and plasma TGF-β1 levels was evaluated by Wilcoxon rank sum test.
Statistical Analysis
Locoregional failure (LRF), distant metastasis (DM), PFS, and OS were as defined in the NRG Oncology RTOG 0522 protocol. The LRF and DM rates were estimated by the cumulative incidence method. 42 The PFS and OS rates were estimated by the Kaplan-Meier method. 43 The HRs were estimated by the Cox proportional hazards model. 32 Adverse events were graded by Common Terminology Criteria for Adverse Events, version 3.0. Odds ratios (ORs) were estimated by logistic regression. Patient characteristics were compared with the Fisher exact test (categorical variables) or Wilcoxon rank sum test (ordinal or continuous variables). All analyses were performed using SAS statistical software, version 9.4 (SAS Institute Inc). P < .05 was considered statistically significant. Figure 1A ). The cetuximab treatment effect significantly varied over time (P = .02 for interaction between treatment and PFS time [>1 year]). In the nonvariant group, there was no effect of cetuximab on PFS with a treatment effect HR (cetuximab vs no cetuximab) of 1.00 (95% CI, 0.72-1.38; P = .98). In multivariate analysis, the interaction among treatment, time (>1 year), and KRAS-variant group remained significant (HR, 0.42; 95% CI, 0.14-1.26, for early treatment effect; HR, 1.22; 95% CI, 0.53-2.80, for late treatment effect; P = .02), indicating that there is an interaction between treatment and time in the KRAS-variant group ( Table 1) . The pattern of failure in a multivariate analysis suggested that DM rather than LRF may be a more likely contributor to the difference in PFS for patients with the KRASvariant: in the KRAS-variant group, the treatment effect is 0.45 (95% CI, 0.12-1.70) for DM and 0.84 (95% CI, 0.29-2.42) for LRF (eFigure 2 and eFigure 3 in the Supplement). In the nonvariant group, the treatment effects are 0.90 (95% CI, 0.48-1.70) for DM and 1.24 (95% CI, 0.80-1.92) for LRF.
Results

Prediction of Response to Cetuximab
Patients with the KRAS-variant also had significantly improved OS in the first 2 years (HR, 0.19; 95% CI, 0.04-0.86; P = .03) but not thereafter (HR, 2.34; 95% CI, 0.58-9.41; P = .23) ( Figure 1B) . Again, the cetuximab treatment effect significantly varied over time (P = .02 for interaction between treatment effect and survival time [>2 years]). In the nonvariant group, cetuximab treatment had no effect on OS (treatment effect HR [cetuximab vs no cetuximab], 0.90; 95% CI, 0.62-1.30; P = .56). In a multivariate analysis, the interaction among treatment, time (>2 years), and KRAS-variant group remained significant ( Table 1 ), indicating that there is an in-
Interaction With p16 Status for PFS
Because p16, a key cell cycle inhibitor, is a known prognostic biomarker in HNSCC, we evaluated outcome in patients with the KRAS-variant while considering p16 status, without or with cetuximab treatment. For PFS, in patients treated without cetuximab, the 2-way interaction between KRAS and p16 was significant ( Table 2 ). The p16-positive patients with the KRASvariant treated without cetuximab had worse PFS than the p16-positive patients without the KRAS-variant (HR, 2.59; 95% CI, 0.91-7.33; P =.07) (Figure 2A) . However, in cetuximab-treated patients, there was no longer a difference in outcome between the p16-positive patients with the KRAS-variant vs without the KRAS-variant (HR, 0.89; 95% CI, 0.34-2.35; P = .82) (Figure 2A ).
Interaction With p16 and Treatment for OS
For OS, there is a significant 3-way interaction among cetuximab treatment, KRAS-variant status, and p16 status. There is also a significant 2-way interaction between treatment and KRAS for p16-positive patients and between treatment and p16 status for patients with the KRAS-variant (Table 2) . In patients treated without cetuximab, p16-positive patients with the KRAS-variant had worse OS than p16-positive patients without the KRAS-variant (HR, 2.48; 95% CI, 0.64-9.65; P = .19), which appeared to be nonsignificantly reversed with cetuximab treatment (HR, 0.22; 95% CI, 0.03-1.66; P = .14) ( Figure 2B ). In p16-positive patients, the cetuximab treatment effect is 0.21 (95% CI, 0.02-2.04; P = .18) for patients with the KRAS-variant compared with 2.36 (95% CI, 0.98-5.67; P = .05) for patients without the KRAS-variant.
Immunologic Landscape and Toxic Effects in Patients With the KRAS-Variant
On the basis of the differential effect of cetuximab, especially in p16-positive patients, we investigated immune factors in patients with the KRAS-variant. We measured plasma TGF-β1 (generally a negative regulator of local immune response) levels in patients from NRG Oncology RTOG 0522 and found that patients with the KRAS-variant had significantly higher plasma TGF-β1 levels (median, 23 376.49 pg/mL; interquartile range, 12 574.03-44 809.10 pg/mL; range, 5034.35-109 758.72 pg/ mL) compared with patients without the KRAS-variant (median, 18 477 pg/mL; interquartile range, 8837.00-32 378.43 pg/ mL; range, 2261.42-123 264.70 pg/mL) (Wilcoxon rank sum test, b First year for PFS and first 2 years for OS.
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Original Investigation Research jamaoncology.com (Reprinted) JAMA Oncology April 2017 Volume 3, Number 4P = .03). The TGF-β1 levels were also compared by p16 and KRAS-variant status, but the differences were not statistically significant in this smaller cohort (eTable 3 in the Supplement). On the basis of the known role of TGF-β1 in normal tissue radiation toxicity, we evaluated toxic effects in patients with and without the KRAS-variant. Patients with the KRASvariant appeared to have elevated levels of grade 3 to 4 mucositis even without cetuximab treatment (47.4% without cetuximab vs 50.0% with cetuximab; OR, 1.11; 95% CI, 0.43-2.85; P = .83). In contrast, in patients without the KRASvariant, the addition of cetuximab significantly increased grade 3 to 4 mucositis (37.9% vs 50.6%; OR, 1.68; 95% CI, 1.09-2.58; P = .02) (eTable 4 in the Supplement). However, a test of the interaction between KRAS-variant status and cetuximab treatment was not significant (ORs, 1.11 and 1.68; P = .43). Patients with the KRAS-variant also appeared to have elevated levels of grade 3 to 4 skin reaction inside the portal even without cetuximab treatment (18.4% without cetuximab vs 15.6% with cetuximab; OR, 0.82; 95% CI, 0.23-2.89; P = .76). In contrast, in patients without the KRAS-variant, the addition of cetuximab significantly increased grade 3 to 4 skin reactions inside the portal (11.2% vs 21.8%; OR, 2.21; 95% CI, 1.21-4.01; P = .05), but again a test of interaction was not significant (P = .16) (eTable 5 in the Supplement). As expected, both patients with and without the KRAS-variant developed increased skin reaction outside the portal with cetuximab (nonvariant OR, 50.15; 95% CI, 6.81-369.54; P < .001; KRAS-variant OR, 8.54; 95% CI, 0.97-75.20; P = .05) (eTable 6 in the Supplement).
To further evaluate whether KRAS-variant status and TGF-β1 levels together predict toxic effects, we evaluated patients with the KRAS-variant with known TGF-β1 levels (n = 65) 
KRAS-variant/p16+
Plus cetuximab A, Progression-free survival. There is a significant 2-way interaction between KRAS-variant status and p16 in patients treated without cetuximab (P = .04). B, Overall survival. There is a significant 3-way interaction among cetuximab treatment, KRAS-variant status, and p16 status (P = .02).
and looked at grade 3 to 4 mucositis or in-field skin toxic effects. We only included patients not treated with cetuximab because cetuximab is known to be a radiosensitizer. We found that patients with the KRAS-variant with TGF-β1 levels greater than vs at the median or below treated without cetuximab appeared to have an increase in risk of grade 3 to 4 toxic effects (OR, 2.31; 95% CI, 0.57-9.41). However, the interaction between the KRAS-variant and TGF-β1 was not significant (P = .40). In contrast, patients without the KRAS-variant with TGF-β1 levels greater than vs at the median or below treated without cetuximab had little correlation of TGF-β1 levels on toxic effects (OR, 1.19; 95% CI, 0.62-2.25).
Discussion
Patients with advanced HNSCC with the KRAS-variant significantly benefit from the addition of cetuximab to radiotherapy and cisplatin therapy, resulting in improved PFS and OS. We found that this benefit fades over time, possibly because of the short course of cetuximab delivered in this study. We further found that there is a significant interaction among the KRAS-variant, p16 status, and cetuximab, with p16-positive patients with the KRAS-variant doing poorly compared with p16-positive patients without the KRAS-variant, a deficit that seems to be overcome by cetuximab. Furthermore, we found that patients with the KRAS-variant have significantly elevated TGF-β1 levels, suggesting that they may have a baseline immunodeficient and/or anti-tumor immunodefective state, which cetuximab in combination with radiotherapy may be helping to overcome.
For HNSCC, although p16 is an important prognostic biomarker, it appears that knowledge of p16 status and KRAS-variant status may be important to determine optimal personalized treatment for these patients. It is particularly notable that p16-positive patients with the KRAS-variant had the worst outcomes of all subgroups of patients with HNSCC in our study, which appeared to be improved with a short course of cetuximab treatment given with radiotherapy and cisplatin. These patients should perhaps be considered a different entity from p16-positive patients without the KRAS-variant, who had excellent outcomes with radiotherapy and cisplatin alone. Work is ongoing to further validate these observations.
Our finding that patients with HNSCC and the KRASvariant may have an altered immune state compared with patients without the KRAS-variant is novel but perhaps not surprising, considering that the KRAS-variant is germline and, thus, present in all cells, including immune cells. This inherited mutation is known to lead to globally altered gene expression profiles consistent with KRAS addiction, 19,23 as well as altered expression of the let-7 microRNA, 40 both of which have significant effects on the immune system.
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In addition, our findings of elevated TGF-β1 expression in these patients, which has long been known to be involved in immunity 35 and immunosuppression, 44 further supports our hypothesis that patients with the KRAS-variant are immunosuppressed. Baseline differences in immunity could also help explain the increased cancer risk found in patients with the KRAS-variant. Interestingly, cetuximab overcomes the impaired natural killer group 2D-dependent functionality of activated natural killer cells 38, 39 in the presence of TGF-β1, 45,46 potentially explaining the global benefit of cetuximab treatment seen in patients with the KRAS-variant. Whether the altered TGF-β1 we see in these patients represents baseline perturbations in homeostasis or altered responses to tumor challenge and is a finding that will be found for all KRAS-variant patients with cancer remains unclear and is the subject of important ongoing investigations. Although the sample size was small in this study and a larger study would strengthen the results, our current findings are consistent with prior work 30 with KRAS-variant patients with recurrent or metastatic HNSCC treated with cisplatin with or without cetuximab, revealing that the addition of cetuximab improved median survival to 3.9 months; however, the interaction with p16 status could not be evaluated previously because of the small sample size. Our findings are also consistent with those found in KRAS-variant patients with colon cancer, in whom cetuximab monotherapy is clearly beneficial. 16, 17 What this study has additionally found is the potential importance of cetuximab delivered in conjunction with radiotherapy for patients with the KRAS-variant to seemingly enable them to mount appropriate immunologic responses after tumor-targeted irradiation, diminishing metastatic failures. We also find that patients with the KRAS-variant may have baseline normal tissue radiation sensitivity, possibly through their elevated TGF-β1 levels. Although cetuximab is a known radiosensitizer, there did not appear to be worsened radiosensitivity with the addition of cetuximab for patients with the KRAS-variant. Studies are ongoing to better understand the mechanisms of radiosensitivity in these patients to further personalize their treatment.
Limitations
This was an ad hoc analysis of a prospective study with a limited number of KRAS-variant patients. Additional prospective trials are planned to directly confirm the findings. End points to be further validated include the findings that the KRAS-variant identifies patients with altered immunity and differential sensitivity to radiotherapy and immunemodulating therapies.
Conclusions
Although a germline biomarker that can identify individuals with altered immunity that can be used to direct the best therapeutic combinations is a bold new concept, the KRAS-variant is unfolding as a true candidate. On the basis of the findings of this study, defining how anticancer agents affecting the tumor-host-immune association differently affect patients with the KRAS-variant is a critical and pressing need because this knowledge could help in personalizing developing immunebased cancer therapies for all patients. Enrolled onto RTOG 0522 (n=940)
Randomly assigned to RT and cisplatin (n=470)
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